Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.66 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.66 |
| ▸ | TEAD1 | P28347 | 3/20 | 0.58 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29456933 | 1.00 | CARM1 (0.66) | CARM1PRMT6TEAD1SMYD3MEN1 | |
| Hydrochloric Acid SCHEMBL30117154 | 0.98 | CARM1 (0.64) | CARM1PRMT6TEAD1SMYD3MEN1 | |
| SCHEMBL4244332 | 0.94 | CARM1 (0.63) | CARM1PRMT6TEAD1MEN1KMT2A | |
| SCHEMBL23200173 | 0.94 | CARM1 (0.63) | CARM1PRMT6TEAD1SMYD3MEN1 | |
| SCHEMBL6858410 | 0.93 | CARM1 (0.62) | CARM1PRMT6TEAD1SMYD3MEN1 | |
| Formic Acid SCHEMBL5076807 | 0.91 | TEAD1 (0.61) | CARM1PRMT6TEAD1SMYD3MEN1 | |
| SCHEMBL375127 | 0.90 | CARM1 (0.59) | CARM1PRMT6TEAD1SMYD3MEN1 | |
| SCHEMBL375071 | 0.90 | CARM1 (0.59) | CARM1PRMT6TEAD1SMYD3MEN1 | |
| SCHEMBL3816081 | 0.90 | CARM1 (0.59) | CARM1PRMT6TEAD1SMYD3MEN1 | |
| Methylene Chloride SCHEMBL27890329 | 0.86 | CARM1 (0.56) | CARM1PRMT6TEAD1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | claimed |
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| EP-3177612-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2022-02-23 | — | — | EP | disclosed |
| US-11254681-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| WO-2021198955-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-10-07 | — | — | WO | disclosed |
| US-20200392140-A1 | OPTIONALLY FUSED HETEROCYCLYL- SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2020-12-17 | — | — | US | disclosed |
| US-10683293-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2020-06-16 | — | — | US | disclosed |
| US-20170342074-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-30 | — | — | US | disclosed |
| US-20170342074-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-30 | — | — | US | disclosed |
| CN-1662498-A | Novel tetrahydropyridine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2005-08-31 | — | — | CN | disclosed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| CN-1649870-A | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD (CH) | 2005-08-03 | — | — | CN | disclosed |
| US-20050132508-A1 | Dry cleaning process | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2005054176-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-1519920-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2005-04-06 | — | — | EP | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004105762-A1 | MEDICAL USE OF DIAZABICYCLONONENE DERIVATIVES AS INHIBITORS OF PARASITE ASPARTIC PROTEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004002957-A1 | NOVEL TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-01-08 | — | — | WO | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254681-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | PPARD, PPARG, RORC | CARM1 933/4885PRMT6 1926/4885TEAD1 1020/4885 |
| US-11780843-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | CARM1 468/4885PRMT6 1352/4885TEAD1 427/4885 |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | CARM1 2909/4885PRMT6 466/4885TEAD1 2874/4885 |
| US-20200392140-A1 | OPTIONALLY FUSED HETEROCYCLYL- SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | CARM1 933/4885PRMT6 1926/4885TEAD1 1020/4885 |
| US-20170342074-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | CARM1 933/4885PRMT6 1926/4885TEAD1 1020/4885 |
| US-10683293-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | PPARD, PPARG, RORC | CARM1 933/4885PRMT6 1926/4885TEAD1 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.